Benralizumab Prefilled Syringe
ApprovedRecruiting 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Asthma; Eosinophilic
Conditions
Asthma; Eosinophilic, Severe Asthma
Trial Timeline
Oct 11, 2021 โ Nov 1, 2026
NCT ID
NCT04565483About Benralizumab Prefilled Syringe
Benralizumab Prefilled Syringe is a approved stage product being developed by AstraZeneca for Asthma; Eosinophilic. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04565483. Target conditions include Asthma; Eosinophilic, Severe Asthma.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04565483 | Approved | Recruiting |
Competing Products
20 competing products in Asthma; Eosinophilic